Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Telitacicept for Prevention of Flares in SLE
NCT06394063Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Renji Hospital. Started Jun 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06394063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394063.